AP
Apogee Therapeutics, Inc.
APGE · NASDAQ
$135.07 +0.01% (+$0.01)
1M +0.21%
Market Cap $8.36B
P/E Ratio -
Div. Yield -
ROE 29.88%
Piotroski F-Score Weak
2/9Valuation
13 /100
Expensive P/B 7.00x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 85.30%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 25.25%
ROE 29.88%
Asset turnover 0.00x
Debt
69 /100
Low Debt/Equity 0.01x
Current ratio 26.44x
Int. coverage -185.14x
Stability
33 /100
Unstable Beta 0.34x
EPS volatility 44.58%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na APGE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Thomas Henderson
Employees
261
Headquarters
Waltham
Nadcházející události
09 LIS
Earnings
Upcoming earnings report